W that diabetes-accelerated atherogenesis is not dependent on PGE2-EP4 signaling

W that diabetes-accelerated atherogenesis is not dependent on PGE2-EP4 signaling in myeloid cells. Together, these results are important because PGE2 production is elevated in inflammatory states, including in some cases diabetes, and PGE2-EP4 has been shown to mediate detrimental effects on the kidney in diabetic mice through increased IL-6 production [22, 25]. Similarly, hematopoietic EP4-deficiency reduces inflammation in a mouse model of multiple sclerosis through a mechanism likely involving get Rocaglamide reduced IL-6 production [49], and EP4 is required for initiation of skin immune responses after antigen exposure by promoting migration of skin dendritic cells [50]. Conversely, hematopoietic EP4-deficiency has been shown to augment inflammation in other states; for example, hematopoietic EP4-deficiency enhances inflammation and aortic aneurysm formation in an Ldlr-/- mouse model [51]. The role of PGE2 in FPS-ZM1MedChemExpress FPS-ZM1 modulating inflammatory processed and atherosclerosis is complex [44], and likely depends on the disease model, timing and cell types involved. The present study is the first, to the best of our knowledge, to address the role of myeloid cell EP4 in a mouse model of diabetes-accelerated atherogenesis. Our results indicate that diabetes acts through other mechanisms to promote atherosclerosis, and further suggest that macrophage production of IL-6 or TNF- might not explain diabetes-accelerated atherogenesis since these cytokines were significantly altered byPLOS ONE | DOI:10.1371/journal.pone.0158316 June 28,15 /EP4, Diabetes, Inflammation and AtherosclerosisEP4-deficiency. However, we cannot rule out the possibility that the divergent effects of EP4 on IL-6 and TNF- result in a zero sum effect on atherogenesis. We show that Ptger4 mRNA levels are elevated in resident peritoneal macrophages from diabetic mice, as compared with non-diabetic littermates. EP4 has previously been shown to be upregulated in macrophages from pristane-treated mice, a model of some aspects of lupus [11] and in a macrophage cell line by a combination of LPS and IFN- stimulation [52]. Our results also suggest that diabetes results in downregulation of EP1 and EP3 in macrophages. Since EP4 acts to increase cAMP levels and EP1 and EP3 act to reduce cAMP levels, the net effect is likely to be an increased cAMP load in macrophages subjected to PGE2 stimulation under diabetic conditions. Different cell types appear to respond differently to diabetes because EP3 is upregulated in islets from diabetic mice, as compared with controls [53]. Several recent papers have addressed the role of PGE2 in atherogenesis in different mouse models. Deletion of mPGES-1, its most proximal synthase, both globally and specifically in myeloid cells markedly reduces atherogenesis in hyperlipidemic Ldlr-/- mice [54, 55]. Loss of hematopoietic EP2 was demonstrated to have no effect on atherogenesis in fat-fed Ldlr-/- mice [40], while studies on EP4 contributions have produced contradictory results [40, 41]. In one study, loss of hematopoietic cell EP4 resulted in a reduction in early lesions, which was attributed to increased apoptosis of macrophages [40]. The EP4-deficient mice did not show differences in plasma lipoproteins, consistent with the present study, and thioglycollate-elicited EP4-deficient macrophages exhibited reduced levels of cytokines, including Il6 [40]. These results are also consistent with our data on resident peritoneal macrophages, which showed a significant reduction in Il6 by.W that diabetes-accelerated atherogenesis is not dependent on PGE2-EP4 signaling in myeloid cells. Together, these results are important because PGE2 production is elevated in inflammatory states, including in some cases diabetes, and PGE2-EP4 has been shown to mediate detrimental effects on the kidney in diabetic mice through increased IL-6 production [22, 25]. Similarly, hematopoietic EP4-deficiency reduces inflammation in a mouse model of multiple sclerosis through a mechanism likely involving reduced IL-6 production [49], and EP4 is required for initiation of skin immune responses after antigen exposure by promoting migration of skin dendritic cells [50]. Conversely, hematopoietic EP4-deficiency has been shown to augment inflammation in other states; for example, hematopoietic EP4-deficiency enhances inflammation and aortic aneurysm formation in an Ldlr-/- mouse model [51]. The role of PGE2 in modulating inflammatory processed and atherosclerosis is complex [44], and likely depends on the disease model, timing and cell types involved. The present study is the first, to the best of our knowledge, to address the role of myeloid cell EP4 in a mouse model of diabetes-accelerated atherogenesis. Our results indicate that diabetes acts through other mechanisms to promote atherosclerosis, and further suggest that macrophage production of IL-6 or TNF- might not explain diabetes-accelerated atherogenesis since these cytokines were significantly altered byPLOS ONE | DOI:10.1371/journal.pone.0158316 June 28,15 /EP4, Diabetes, Inflammation and AtherosclerosisEP4-deficiency. However, we cannot rule out the possibility that the divergent effects of EP4 on IL-6 and TNF- result in a zero sum effect on atherogenesis. We show that Ptger4 mRNA levels are elevated in resident peritoneal macrophages from diabetic mice, as compared with non-diabetic littermates. EP4 has previously been shown to be upregulated in macrophages from pristane-treated mice, a model of some aspects of lupus [11] and in a macrophage cell line by a combination of LPS and IFN- stimulation [52]. Our results also suggest that diabetes results in downregulation of EP1 and EP3 in macrophages. Since EP4 acts to increase cAMP levels and EP1 and EP3 act to reduce cAMP levels, the net effect is likely to be an increased cAMP load in macrophages subjected to PGE2 stimulation under diabetic conditions. Different cell types appear to respond differently to diabetes because EP3 is upregulated in islets from diabetic mice, as compared with controls [53]. Several recent papers have addressed the role of PGE2 in atherogenesis in different mouse models. Deletion of mPGES-1, its most proximal synthase, both globally and specifically in myeloid cells markedly reduces atherogenesis in hyperlipidemic Ldlr-/- mice [54, 55]. Loss of hematopoietic EP2 was demonstrated to have no effect on atherogenesis in fat-fed Ldlr-/- mice [40], while studies on EP4 contributions have produced contradictory results [40, 41]. In one study, loss of hematopoietic cell EP4 resulted in a reduction in early lesions, which was attributed to increased apoptosis of macrophages [40]. The EP4-deficient mice did not show differences in plasma lipoproteins, consistent with the present study, and thioglycollate-elicited EP4-deficient macrophages exhibited reduced levels of cytokines, including Il6 [40]. These results are also consistent with our data on resident peritoneal macrophages, which showed a significant reduction in Il6 by.